Home › Compare › LOBEF vs EQR

LOBEF vs EQR: Dividend Comparison 2026

LOBEF yields 3861.00% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LOBEF wins by $5102776617539.96M in total portfolio value
10 years
LOBEF
LOBEF
● Live price
3861.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5102776617540.00M
Annual income
$4,855,397,881,919,778,000.00
Full LOBEF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — LOBEF vs EQR

📍 LOBEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLOBEFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LOBEF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
LOBEF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LOBEF
Annual income on $10K today (after 15% tax)
$328,185.33/yr
After 10yr DRIP, annual income (after tax)
$4,127,088,199,631,811,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, LOBEF beats the other by $4,127,088,199,631,808,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LOBEF + EQR for your $10,000?

LOBEF: 50%EQR: 50%
100% EQR50/50100% LOBEF
Portfolio after 10yr
$2551388308770.02M
Annual income
$2,427,698,940,959,891,000.00/yr
Blended yield
95.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

LOBEF
No analyst data
Altman Z
-9.3
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LOBEF buys
0
EQR buys
0
No recent congressional trades found for LOBEF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLOBEFEQR
Forward yield3861.00% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$5102776617540.00M ✓$40.5K
Annual income after 10y$4,855,397,881,919,778,000.00 ✓$3,819.61
Total dividends collected$5085877075297.57M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: LOBEF vs EQR ($10,000, DRIP)

YearLOBEF PortfolioLOBEF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$396,800$386,100.39$11,248$547.57+$385.6K → LOBEF
2$14,742,780$14,318,203.95$12,701$666.53+$14.73M → LOBEF
3$512,952,973$497,178,198.17$14,405$814.59+$512.94M → LOBEF
4$16,715,748,598$16,166,888,916.48$16,413$999.84+$16715.73M → LOBEF
5$510,255,139,456$492,369,288,456.53$18,795$1,232.92+$510255.12M → LOBEF
6$14,592,492,784,652$14,046,519,785,434.00$21,639$1,527.95+$14592492.76M → LOBEF
7$391,042,310,644,499$375,428,343,364,921.60$25,057$1,903.80+$391042310.62M → LOBEF
8$9,820,789,713,309,148$9,402,374,440,919,534.00$29,197$2,385.87+$9820789713.28M → LOBEF
9$231,195,080,018,900,830$220,686,835,025,660,030.00$34,250$3,008.70+$231195080018.87M → LOBEF
10$5,102,776,617,540,002,000$4,855,397,881,919,778,000.00$40,467$3,819.61+$5102776617539.96M → LOBEF

LOBEF vs EQR: Complete Analysis 2026

LOBEF — Stock

Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.

Full LOBEF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this LOBEF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LOBEF vs SCHDLOBEF vs JEPILOBEF vs OLOBEF vs KOLOBEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.